資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/32615
|
| 標題: | Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections |
| 作者: | Lai, Chih-Cheng
Chen, Chi-Chung
Hung-Jen Tang(湯宏仁) |
| 貢獻者: | Kaohsiung Vet Gen Hosp, Dept Internal Med, Tainan Branch
Chi Mei Med Ctr, Dept Med Res
Natl Chiayi Univ, Dept Food Sci
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Chi Mei Med Ctr, Dept Med |
| 關鍵字: | meropenem-vaborbactam
acute bacterial infection
complicated urinary tract infection/acute pyelonephritis |
| 日期: | 2019-10 |
| 上傳時間: | 2020-07-29 13:52:12 (UTC+8) |
| 出版者: | MDPI |
| 摘要: | This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and tolerability of meropenem-vaborbactam and piperacillin-tazobactam in the treatment of complicated urinary tract infection (cUTI)/acute pyelonephritis (APN). TANGO II compared the effect and safety of meropenem-vaborbactam and best-available therapy in the treatment confirmed/suspect carbapenem-resistant Enterobacteriaceae infections. The clinical cure rates at end of treatment (EOT) and test of cure (TOC) among the meropenem-vaborbactam group were non-inferior to those of the control group (at EOT, 92.5% versus 89.3%, risk ratio (RR) 1.27, 95% CI 0.64-2.50; at TOC, 86.2% versus 81.7%, RR 1.37, 95% CI 0.62-3.01). Meropenem-vaborbactam was non-inferior to comparators for microbiological eradication at EOT and TOC (at EOT, 93.3% versus 88.3%, RR 1.21, 95% CI 0.74-1.97; at TOC, 66.5% versus 59.9%, RR 1.12, 95% CI 0.97-1.30). In the subgroup of patients with cUTI/APN, meropenem-vaborbactam had similar overall success rate to the control group at EOT (RR 1.05, 95% CI 1.01-1.09) and at TOC (RR 1.05, 95% CI 0.93-1.19). Meropenem-vaborbactam had a similar risk of treatment-emergent adverse events, events leading to discontinuation of the study drug, any serious adverse events, life-threatening adverse events, drug-related adverse events, and risk of death to comparators. In conclusion, meropenem-vaborbactam was noninferior to comparators for clinical cure and microbiological eradication in the treatment of acute bacterial infection, particularly cUTI/APN, and meropenem-vaborbactam was as tolerable as comparators. |
| 關聯: | Journal of Clinical Medicine, v.8, n.10, 650 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 10.3390-jcm8101650.pdf | | 1264Kb | Adobe PDF | 342 | 檢視/開啟 | | index.html | | 0Kb | HTML | 1109 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
